STOCK TITAN

ProPhase Labs, Inc. - $PRPH STOCK NEWS

Welcome to our dedicated page for ProPhase Labs news (Ticker: $PRPH), a resource for investors and traders seeking the latest updates and insights on ProPhase Labs stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProPhase Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProPhase Labs's position in the market.

Rhea-AI Summary

ProPhase Labs Inc. (NASDAQ: PRPH) will present its first quarter 2024 financial results on May 9, 2024, through a virtual conference call hosted by Renmark Financial. Stakeholders, investors, and followers can register to attend the live event, with a press release outlining the results to be issued beforehand. A replay will be available on the company's Investor website post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences earnings
-
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024, at 11:30 am PST, with CEO Ted Karkus hosting the presentation. 1x1 investor meetings will be held on Thursday, May 2, 2024. For more information and to access the live presentation, visit the provided webcast link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences
-
News
Rhea-AI Summary
ProPhase Labs introduces Project ZenQ-AI, leveraging AI, genomics, and esophageal cancer insights for ADC development. The project utilizes a vast genomic database and BE-Smart test to identify potential ADC candidates for personalized cancer treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.32%
Tags
AI
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announced progress on its BE-Smart test for esophageal cancer, targeting a commercial launch in the second half of 2024. The test aims to revolutionize esophageal cancer detection with reimbursement rates of $1,000 to $2,000 per test. ProPhase collaborates with mProbe Inc. and aims to capture a significant share of the multi-billion-dollar market for esophageal adenocarcinoma diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary
ProPhase Labs, Inc. grants an inducement stock option to purchase up to 50,000 shares of common stock to Lance Bisesar, the new Controller. The option award will vest over four years, with a strike price of $6.20 per share and a 7-year exercise period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Summary
ProPhase Labs, Inc. (PRPH) reports financial and operational results for 2023, highlighting significant capacity expansion and growth at Pharmaloz Manufacturing. Nebula Genomics secures major international B2B deal, while Pharmaloz accelerates capacity expansion. The Company transitions to a genomics lab, anticipates rapid revenue growth, and plans a conference call on March 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
Rhea-AI Summary
ProPhase Labs Inc. (NASDAQ: PRPH) will present its full year 2023 financial results on a virtual conference call on March 15, 2024, hosted by Renmark Financial. Stakeholders, investors, and followers are invited to register and attend the live event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
conferences earnings
-
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces advancements in commercializing BE-Smart esophageal cancer diagnostic test. The test shows promising results in detecting early signs of cancer in individuals with Barrett's esophagus, potentially revolutionizing cancer diagnosis and management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces positive preliminary results for Equivir dietary supplement trial, showing potential to reduce upper respiratory illnesses. Second trial completion expected in Q2 2024, with plans for commercialization and product launch in late 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
Rhea-AI Summary
Sidus Space (NASDAQ: SIDU) has announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024. Mr. White brings over 30 years of experience in financial management, operations, and business development. He has previously served as CFO of ProPhase Labs, Inc. and Intellicheck, Inc. Teresa Burchfield will step down as CFO after two years with the Company but will remain in an advisory role to assist with the transition. The CEO expressed gratitude for Burchfield's contributions and looks forward to the future growth and value creation under White's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
management
ProPhase Labs, Inc.

Nasdaq:PRPH

PRPH Rankings

PRPH Stock Data

96.54M
14.05M
22.06%
9.54%
1.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About PRPH

prophase labs is a diversified natural health medical science company. for more information visit us at www.prophaselabs.com.